Advertisement

CardioVasc

, Volume 19, Issue 1, pp 33–38 | Cite as

Medikamentöse versus invasive Blutdrucktherapie

Haben interventionelle Hochdruckverfahren eine Zukunft?

  • Christopher Gohlisch
  • Alexander ReshetnikEmail author
Zertifizierte Fortbildung Schwerpunkt Hypertonie
  • 216 Downloads

Zusammenfassung

Invasive Verfahren sind kein ultimatives Allheilmittel in der Hypertonietherapie, sie senken den Blutdruck nur moderat und sind deutlich teurer als die medikamentöse Therapie. Trotzdem haben sie ihre Daseinsberechtigung, denn in besonderen Fällen sehen wir nach wie vor die Indikation für invasive Hochdruckverfahren gegeben.

Literatur

  1. 1.
    Peet MM. Hypertension and its surgical treatment by bilateral supradiaphragmatic splanchnicectomy. Am J Surg. 1948;75:48–68CrossRefGoogle Scholar
  2. 2.
    Hoobler SW et al. The effects of splanchnicectomy on the blood pressure in hypertension; a controlled study. Circulation. 1951;4:173–83CrossRefGoogle Scholar
  3. 3.
    Symplicity HTNI, Esler MD et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903–9CrossRefGoogle Scholar
  4. 4.
    Krum H et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383:622–9CrossRefGoogle Scholar
  5. 5.
    Cuspidi C et al. Treatment of hypertension: The ESH/ESC guidelines recommendations. Pharmacol Res. 2018;128:315–321CrossRefGoogle Scholar
  6. 6.
    Townsend RR et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390:2160–70CrossRefGoogle Scholar
  7. 7.
    Azizi M et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335–45CrossRefGoogle Scholar
  8. 8.
    Rosa J et al. Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension: One-Year Outcomes of Randomized PRAGUE-15 Study. Hypertension. 2016;67:397–403CrossRefGoogle Scholar
  9. 9.
    Ott C, et al. Renal denervation in moderate treatment-resistant hypertension. J Am Coll Cardiol. 2013;62:1880–6CrossRefGoogle Scholar
  10. 10.
    Zweiker D et al. Effects of Renal Denervation Documented in the Austrian National Multicentre Renal Denervation Registry. PLoS One. 2016;11:e0161250CrossRefGoogle Scholar
  11. 11.
    Schmieder RE et al. Disproportional decrease in office blood pressure compared with 24-hour ambulatory blood pressure with antihypertensive treatment: dependency on pretreatment blood pressure levels. Hypertension. 2014;64:1067–72CrossRefGoogle Scholar
  12. 12.
    Courand PY et al. Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) Trial. J Am Heart Assoc. 2017;6(10). https://doi.org/10.1161/JAHA.117.007062.
  13. 13.
    Kandzari DE et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36:219–27CrossRefGoogle Scholar
  14. 14.
    Reshetnik A et al. Predictors for success in renal denervation-a single centre retrospective analysis. Sci Rep. 2018;8:15505CrossRefGoogle Scholar
  15. 15.
    Lobo MD et al. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. Lancet. 2015;385:1634–41CrossRefGoogle Scholar
  16. 16.
    Wallbach M et al. Effects of Baroreflex Activation Therapy on Ambulatory Blood Pressure in Patients With Resistant Hypertension. Hypertension. 2016;67(4):701–9CrossRefGoogle Scholar
  17. 17.
    Bisognano JD et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58:765–73.CrossRefGoogle Scholar
  18. 18.
    Wachter R et al. An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems. J Am Soc Hypertens. 2017;11:81–91CrossRefGoogle Scholar
  19. 19.
    Spiering W et al. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet. 2017;390:2655–61CrossRefGoogle Scholar
  20. 20.
    Kandzari DE et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346–55CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Charité — Universitätsmedizin Berlin, Campus Benjamin Franklin, CharitéCentrum 13 — Schwerpunkt Nephrologie, Transplantationszentrum/HypertoniezentrumBerlinDeutschland

Personalised recommendations